To find
Search
New
GE2020
COVID-19
Lifestyle
Trend
Drama
Things to eat
Things to do
Stories of us
Celebrity
Spore anguish
In my humble opinion
Videos
Foreign
Weekend
More
Technology
Viewpoints
Parliament
The story
Environment
AHTC test
Racing
To find
New
GE2020
COVID-19
Lifestyle
Trend
Drama
Things to eat
Things to do
Stories of us
Celebrity
Anguish S’pore
In my humble opinion
Videos
Foreign
Weekend
More
Technology
Viewpoints
Parliament
The story
Environment
AHTC test
Racing
To find
Back
Another candidate in the race to expand an effective vaccine opposed to Covid-19 showed effects in a small study.
The experimental vaccine manufactured through Novavax Inc has effectively produced antibodies opposed to the Covid-19 virus and appears to be safe, Reuters reported.
Supported through the U.S. government.
The Novavax vaccine is one of the few systems funded by the U.S. government under “Operation Warp Speed”. This is the hope of the U.S. government. To boost progression and pandemic-friendly vaccines.
The U.S. government agreed in July to pay $1.6 billion to cover the company’s costs of study and operations. The deal will also pay the company to produce a hundred million doses of the vaccine until early next year if the trials are successful, according to the New York Times.
Positive results
The candidate vaccine is called NVX-CoV2373. It is a vaccine developed from the genetic series of the coronavirus itself, another of other Covid-19 vaccines being investigated.
The exam, which began in May, involved 131 participants between the ages of 18 and 59, according to a press release from Novavax Inc.
They tested the vaccine in two other doses: five micrograms and 2 five micrograms. They also tested the vaccine with and the addition of an adjuvant, which is a substance designed to stimulate the body’s immune response.
These 4 variants were randomly tested on 106 participants. The remaining 25 participants won a placebo.
Novavax also wrote that the vaccine was well-tolerated with only mild side effects.
The corporation stated that participants developed antibodies and “viral neutralization responses” that “were positively compared to responses from” patients recovered from Covid-19.
The only appearance effects observed were swelling and pain in injection after the first dose, and some participants reported headaches, fatigue and muscle pain.
According to CNBC, one player reported a mild fever after the time of the dose.
Novavax’s leading director of studies, Gregory Glenn, said the company would soon begin large-scale testing and hoped to get approval from the fitness board until December, Reuters reported.
Related History:
Getty’s top symbol.